EMA Authorised: Lenalidomide Mylan (lenalidomide) — Mylan Pharmaceuticals Limited

View source ↗

Summary

Lenalidomide Mylan has been authorised in the EU for use in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide Mylan (lenalidomide)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Mylan Pharmaceuticals Limited. Decision date: 08/06/2026